Alkermes plc. Current Federal Tax Expense (Benefit)
Alkermes plc. (ALKS) reported Current Federal Tax Expense (Benefit) of $25.64 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2025-02-12
- Alkermes plc. current federal tax expense (benefit) for fiscal 2024 was $25.64M.
- Alkermes plc. current federal tax expense (benefit) for fiscal 2023 was -$981.00K, a 108.78% decline from fiscal 2022.
- Alkermes plc. current federal tax expense (benefit) for fiscal 2022 was $11.17M, a 396.18% increase from fiscal 2021.
- Alkermes plc. current federal tax expense (benefit) for fiscal 2021 was $2.25M, a 23.51% decline from fiscal 2020.
| Period end | Current Federal Tax Expense (Benefit) 12 month | Current Federal Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2024-12-31 | $25.64M 10-K · filed 2025-02-12 | |
| 2023-12-31 | -$981.00K 10-K · filed 2025-02-12 | |
| 2022-12-31 | $11.17M 10-K · filed 2025-02-12 | $18.11M 10-K · filed 2023-02-16 |
| 2021-12-31 | $2.25M 10-K · filed 2024-02-21 | $2.70M 10-K · filed 2022-02-16 |
| 2020-12-31 | $2.94M 10-K · filed 2023-02-16 | |
| 2019-12-31 | -$471.00K 10-K · filed 2022-02-16 | |
| 2018-12-31 | -$53.00K 10-K · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |